Drugs can be made 'smarter'
A new method has been developed to make drugs 'smarter' using nanotechnology so they will be more effective at reaching their target.
Scientists from the University of Lincoln, UK, have devised a new technique to 'decorate' gold nanoparticles with a protein of choice so they can be used to tailor drug to more accurately target an area on the body, such as a cancer tumour.
Gold nanoparticles are spheres made of gold atoms having a diameter of only few billionths of a metre which can be coated with a biological protein and combined with drugs to enable the treatment to travel through the body and reach the affected area.
The nanoparticles can 'adsorb' (hold on its surface) drugs which would otherwise become insoluble or quickly degrade in the blood stream, and due to their small size they can overcome biological barriers such as membranes, skin and the small intestine which would usually prevent the drug from reaching its target.
The technology is already used in real world applications such as pregnancy tests - where gold nanoparticles decorated with an antibody against the hormone present in the urine of pregnant women is added to the 'positive' strip so it reacts with the nanoparticles to turn the stick red - but is not yet widely used in drug development.
Until now the process of coating the nanoparticles meant that the proteins used had to be 'mixed' together with particles which do not have the ability to control the way they bind, possibly making the drug less effective. The new method enables pharmacologists to place the proteins onto the gold nanoparticles layer by layer in a specific order. This maintains the integrity of the protein so that the drug is more effective, opening up possibilities for the development of nanomedicine.
Dr Enrico Ferrari, a nanobiotechnologist from the University of Lincoln's School of Life Sciences, led the study. He said: "Gold nanoparticles are a vital tool in new drug development and drug delivery systems. We have unlocked the key to binding proteins and molecules so that those drugs will be more effective.
"This method might help to design nanomedicines that do not need extensive chemical modification of a protein drug or a nano-carrier and therefore can be developed more easily and faster."
Researchers took fragments of proteins from bacteria and flatworms, which when fused together were effective at binding to the gold nanoparticle surface and able to form stable bonds to any other protein.
By mixing this fusion protein with gold nanoparticles, it permanently binds to the gold surface while also being able to stably bind a target protein on which a specific 'tag' was included.
This is a new universal method to bind proteins to nanoparticles which will work for most proteins, making the process a more attractive prospect for pharmaceutical companies, the researchers said. The method could also potentially be applied to biosensors and diagnostic kits that use gold, such as those used in clinical settings to identify ongoing infections in patients' blood.
Original publication
Other news from the department science
These products might interest you

DynaPro Plate Reader III by Wyatt Technology
Screening of biopharmaceuticals and proteins with high-throughput dynamic light scattering (DLS)
Efficiently characterize your sample quality and stability from lead discovery to quality control

Eclipse by Wyatt Technology
FFF-MALS system for separation and characterization of macromolecules and nanoparticles
The latest and most innovative FFF system designed for highest usability, robustness and data quality

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.